{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:43:02Z","timestamp":1793508182658,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104820","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:52:05Z","timestamp":1780037525000},"page":"104820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-3224","authenticated-orcid":false,"given":"Roberto","family":"Buonaiuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8185-2492","authenticated-orcid":false,"given":"Federica Pia","family":"Mangiacotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-3479","authenticated-orcid":false,"given":"Fabiola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8883-1426","authenticated-orcid":false,"given":"Margherita","family":"Tafuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9949-0427","authenticated-orcid":false,"given":"Roberta","family":"Scarfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Longobardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-2577","authenticated-orcid":false,"given":"Martina","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-4333","authenticated-orcid":false,"given":"Aldo","family":"Caltavituro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-3153","authenticated-orcid":false,"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-4630","authenticated-orcid":false,"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1572","authenticated-orcid":false,"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104820_bib1","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104820_bib2","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.3390\/cancers15164190","article-title":"Extended adjuvant endocrine therapy in early breast cancer patients\u2014review and perspectives","volume":"15","author":"Bekes","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104820_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1748-717X-5-2","article-title":"Multidisciplinary approach of early breast cancer: the biology applied to radiation oncology","volume":"5","author":"Bourgier","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2026.104820_bib5","first-page":"80","article-title":"Evidence-based evaluation of benefits in therapeutic interventions: methodologically controlled and non-randomly assigned reflections on the number needed to treat","volume":"4","author":"Gensini","year":"2003","journal-title":"Ital Heart J"},{"key":"10.1016\/j.breast.2026.104820_bib6","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104820_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.seminoncol.2024.12.001","article-title":"The likelihood of being helped or harmed obtained from clinical trial results for cancer therapy: can it really help?","volume":"52","author":"Bronte","year":"2025","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib9","doi-asserted-by":"crossref","unstructured":"Gradishar, W. J., Moran, M. S., Abraham, J., et al. (2025). Breast cancer, version 5.2025 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw, 23(11), 426-436. doi: 10.6004\/jnccn.2025.0053. n.d.","DOI":"10.6004\/jnccn.2025.0053"},{"key":"10.1016\/j.breast.2026.104820_bib10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-year Follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-Positive breast cancer","volume":"7","author":"van der Voort","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib11","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104820_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published kaplan-meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.breast.2026.104820_bib13","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.4088\/JCP.15f09870","article-title":"The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they Do not","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.breast.2026.104820_bib14","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2026.104820_bib15","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2146\/ajhp040558","article-title":"Number needed to treat: a descriptor for weighing therapeutic options","volume":"62","author":"Wen","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.breast.2026.104820_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jclinepi.2009.08.006","article-title":"Common problems related to the use of number needed to treat","volume":"63","author":"Stang","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.breast.2026.104820_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1503\/cmaj.080484","article-title":"The \u201cnumber needed to treat\u201d turns 20 -- and continues to be used and misused","volume":"179","author":"McAlister","year":"2008","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.breast.2026.104820_bib18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2026.104820_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-Positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104820_bib20","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.23.02505","article-title":"Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2\u2013Positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update","volume":"42","author":"Loibl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105112","article-title":"LBA1 adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: final analysis at 11.3 years' median follow-up","volume":"10","author":"Loibl","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104820_bib22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104820_bib24","article-title":"Overall survival with abemaciclib in early breast cancer","author":"Johnston","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-Year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104820_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS1-09","article-title":"Abstract GS1-09: olympia: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (Neo)adjuvant chemotherapy in patients w\/germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer","volume":"31","author":"Garber","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104820_bib27","doi-asserted-by":"crossref","first-page":"S1204","DOI":"10.1016\/j.annonc.2024.08.2247","article-title":"LBA4 neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: overall survival results from the phase III KEYNOTE-522 study","volume":"35","author":"Schmid","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN Clinical Practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104820_bib29","unstructured":"EMA approval, 12.09.2018; Reference Number:EMA\/455200\/2018 n.d."},{"key":"10.1016\/j.breast.2026.104820_bib30","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1158\/1078-0432.CCR-18-3003","article-title":"FDA approval summary: pertuzumab for adjuvant treatment of HER2-Positive early breast cancer","volume":"25","author":"Howie","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104820_bib45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104820_bib47","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer in the APHINITY trial: 6 years' Follow-Up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib49","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, Node-Positive, High-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib plus endocrine therapy in hormone Receptor\u2013Positive\/ERBB2-Negative early breast cancer","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104820_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104820_bib33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/13696998.2025.2466365","article-title":"Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico","volume":"28","author":"Wurcel","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.breast.2026.104820_bib34","first-page":"482","article-title":"Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia","volume":"31","author":"Chanan-Khan","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.breast.2026.104820_bib35","first-page":"110","article-title":"Reporting number needed to treat requires standardization","volume":"113","author":"Temple","year":"2026","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.breast.2026.104820_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.31914","article-title":"Ten\u2010year recurrence rates for breast cancer subtypes in the Netherlands: a large population\u2010based study","volume":"144","author":"van Maaren","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104820_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(19)33102-2","article-title":"Carryover effects of aromatase inhibitors in prevention","volume":"395","author":"Chumsri","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104820_bib38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104820_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.breast.2026.104820_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2288-9-21","article-title":"Calculation of NNTs in RCTs with time-to-event outcomes: a literature review","volume":"9","author":"Hildebrandt","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.breast.2026.104820_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111924","article-title":"The number needed to treat: it is time to bow out gracefully","volume":"187","author":"Murad","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.breast.2026.104820_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103496","article-title":"Communication and support of patients and caregivers in chronic cancer care: ESMO clinical practice guideline","volume":"9","author":"Stiefel","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104820_bib43","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s11136-020-02503-8","article-title":"Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods","volume":"29","author":"van de Water","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.breast.2026.104820_bib44","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/pon.6247","article-title":"Harmful communication behaviors in cancer care: a systematic review of patients and family caregivers perspectives","volume":"32","author":"Westendorp","year":"2023","journal-title":"Psychooncology"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:28:00Z","timestamp":1784928480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S096097762600130X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104820","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104820"}}